Analysts Reaffirm Buy Rating for Zentalis Amid Stock Challenges Despite recent stock declines, HC Wainwright reiterated a "buy" rating for Zentalis Pharmaceuticals with a $10 price target, suggesting significant upside potential. Other analysts maintain mixed ratings, with price targets ranging from $2.20 to $8.00, reflecting uncertainty around the company's near-term performance.45